Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CSGALNACT1 | Q8TDX6 | 17/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297794 | 1.00 | RAB9A (0.54) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2298410 | 0.94 | CSGALNACT1 (0.56) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2293612 | 0.91 | CSGALNACT1 (0.56) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2295109 | 0.89 | MEN1 (0.58) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2295116 | 0.89 | MEN1 (0.58) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2297267 | 0.87 | CSGALNACT1 (0.59) | CSGALNACT1ALDH1A1 | |
| SCHEMBL2297270 | 0.87 | CSGALNACT1 (0.59) | CSGALNACT1ALDH1A1 | |
| SCHEMBL2297930 | 0.87 | CSGALNACT1 (0.67) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2294524 | 0.86 | CSGALNACT1 (0.59) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2294246 | 0.83 | CSGALNACT1 (0.68) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | RAB9A 3753/4885MEN1 4530/4885KMT2A 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.